Multiplier potential with AI newcomer NetraMark! Palantir and BioNTech in one share!

NetraMark Holdings: AI hidden gem set for a breakthrough in 2025

NetraMark is still an AI hidden gem. However, this could change dramatically soon, as evidenced by the Company's news flow and share price jump. There is now also liquid trading on German stock exchanges. Yet the technology company is still valued at less than CAD 100 million. In the current year, the operational breakthrough in the billion-dollar market is expected to be achieved. How this will happen will be presented by the Company on February 25, 2025, at the virtual investor conference IIF. Free registration here).

What does NetraMark Holdings do? The technology company wants to revolutionize the way clinical trials are conducted in the biotech and pharmaceutical industry. To do this, it has developed software based on artificial intelligence (AI) and machine learning (ML). Using a novel topology-based algorithm, patient data sets can be broken down into subsets of strongly linked individuals based on several variables. As a result, NetraMark can work with much smaller data sets to categorize diseases into different types, classify patients for drug sensitivity, and, of course, evaluate treatment efficacy.

NetraMark has the answer to a major challenge in AI for clinical trials. AI and ML models thrive on huge amounts of data, but clinical trials usually involve a few hundred patients. However, thanks to the NetraMark algorithm, even these smaller datasets are sufficient to provide real value to customers: finding the intersection between efficacy and feasibility to improve decision-making, shorten trial times, and ultimately reduce costs and bring the drug to market faster.

Last week, the latest version, NetraAI 2.0, was presented to analyze and improve clinical studies. With just 30 patients, a meaningful patient group can already be established. This is a major advantage because patient recruitment often poses significant challenges for the timeline and budget. Reporting for decision-makers has also been optimized with NetraAI 2.0. Among other features, the AI reports its results after prioritization. In addition, the software provides real-time insights into the progress during the study and checks compliance with the study objectives. This allows for quick action if needed. Recommendations are also given for dose selection. Overall, NetraMark should attract numerous new customers with NetraAI 2.0 in the current year.

Top 5 company as a reference customer

NetraMark has also managed to secure a strong reference customer. The collaboration with a Top 5 company in the industry began in 2025. The pharmaceutical company will use the NetraAI software in the pilot project to improve the development of new therapeutics for the treatment of autoimmune diseases. NetraAI will analyze critical research areas, including the effects of drugs, surgical and medical interventions in the past, and the refinement of subtypes of autoimmune diseases. The insights gained will drive innovation in treatment strategies and patient care.

AI in medicine: A market worth billions

With the ability to draw important conclusions from studies with just a few patients, NetraMark has a real competitive advantage and great opportunities in a market worth billions. In 2024, around USD 3 billion is expected to have been generated with AI in the pharmaceutical industry. In 2029, it is expected to be around USD 18 billion (source: Mordorintelligence.com). This would mean that the market would grow by an impressive 42.7% per year. The growth prospects in the clinical research sub-sector are also impressive. Between 2021 and 2029, revenues from the use of AI are expected to increase from USD 1.3 billion to USD 5.6 billion.

Top management strengthened and financing secured

Just in time for the new software and the top customer, NetraMark has strengthened its top management and secured financing. Dr. Angelico Cart has been appointed Chief Strategy Officer. He is co-founder of Worldwide Clinical Trials and has more than 35 years of experience in clinical research and pharmaceutical strategy. This means he knows exactly what potential customers expect and can influence the further development of the software accordingly. P.J. Haley is also new to the board. He comes from the pharmaceutical industry and has over 20 years of experience in oncology commercialization, market access, and strategic partnerships. Accordingly, Haley is expected to drive NetraMark's expansion in oncology.

NetraMark has also already secured the growth financing. At the beginning of the year, the AI company received around CAD 1.16 million through the exercise of warrants and stock options.

Conclusion: AI stock with multiplication potential

NetraMark's stock has significant multiplication potential. The Company is active in a growing billion-dollar market and possesses a competitive advantage with its ability to deliver added value from smaller data sets within clinical trials. The first top company has been secured as a customer. If the positive development continues, the stock, with a market capitalization of under CAD 100 million, represents a real bargain.